Risk factor
Moderate default risk
Profitability factor
Greatly undervalued vs peers
About
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'c
Target Price
The average target price of ILM1.DE is 21.4 and suggests 71.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i